HeartBeam (NASDAQ: BEAT) announced a strategic reorganization aimed at accelerating execution, expanding global market reach and improving capital efficiency as it advances commercialization of its cardiac monitoring technology. Under the new structure, Founder and President Branislav Vajdic, Ph.D., and Executive Chairman Rich Ferrari will lead focused implementation teams designed to streamline decision-making, improve accountability and reduce costs. As part of the transition, former CEO Robert Eno will move into a consulting role.
The company said its strategy centers on leveraging its patented 3D ECG platform across multiple healthcare channels while advancing development beyond arrhythmia assessment toward heart attack detection. HeartBeam also plans to expand partnerships with governments, health systems, ECG manufacturers and wearable device companies, building on its December 2025 FDA clearance for its synthesized 12-lead ECG technology for arrhythmia assessment. The full press release is available at https://ibn.fm/CTxXi.
HeartBeam's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-lead ECG synthesis software in December 2025. The company holds over 20 issued patents related to technology enablement. By reorganizing, HeartBeam aims to reduce costs and improve accountability, positioning itself to capture a larger share of the cardiac monitoring market. The move underscores the company's commitment to bringing its cable-free, portable ECG device to patients worldwide, enabling physicians to identify cardiac health trends and acute conditions outside of medical facilities.
This reorganization comes at a critical time as HeartBeam seeks to commercialize its technology globally. The company's platform is designed for portable devices that can collect ECG signals in 3D from three non-coplanar directions and synthesize them into a 12-lead ECG. This innovation allows for actionable heart intelligence to be delivered wherever the patient is, potentially redefining cardiac health management. With FDA clearances in hand, HeartBeam is now focused on expanding partnerships with key stakeholders, including governments, health systems, and wearable device companies.
Investors can find the latest news and updates relating to BEAT in the company’s newsroom at https://ibn.fm/BEAT. Forward-looking statements in this release involve risks and uncertainties as detailed in the company's SEC filings.
